Targeted inhibition of the anti-apoptotic Bcl-2 proteins has been shown to have impressive efficacy in the treatment of several hematologic malignancies, with current FDA approvals of venetoclax for the treatment of CLL and AML. This evidence concerns the gene BCL2 and hematologic disorder.